Nektar Inks $1.85B Bristol-Myers Cancer Drug Collaboration

Law360 (February 14, 2018, 2:13 PM EST) -- Nektar Therapeutics has inked a $1.85 billion cash-and-stock deal to jointly develop and manage its cancer-fighting, immuno-stimulatory therapy in combination with two Bristol-Myers Squibb cancer treatments, the companies said Wednesday.

According to the joint announcement, Bristol-Myers Squibb Co. has agreed to pay Nektar $1 billion in cash and buy $850 million worth of Nektar shares at $102.60 a piece. Nektar could also pocket roughly $1.78 billion in development, regulatory and sales milestones, the announcement added.

The companies said they will split global profits for the therapy,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.